NEW YORK – Quantgene and CureMatch said on Wednesday that they have signed a strategic partnership to integrate genomic, cloud, and artificial intelligence technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer.
The firms also said that they plan to collaborate on advancing genomics and AI-guided oncology tools.
Santa Monica, California-based Quantgene said its Quantgene Liquid assay profiles cell-free DNA in blood samples from cancer patients to establish their mutational profiles.
"Deep genomics and AI can be a game-changer for cancer patients, [as] new combination treatments can significantly improve outcomes," Jo Bhakdi, founder and CEO of Quantgene, said in a statement. "With CureMatch, we can make precision treatment insights available to everyone through a simple blood draw."
San Diego-based CureMatch's Decision Support System leverages proprietary algorithms, as well as curated clinical and scientific knowledge to provide a matching score to help doctors identify combinations and monotherapies for optimal cancer treatment.
By integrating both technologies, the firms believe patients and oncologists will have access to a workflow that only requires a blood draw to match them to appropriate cancer therapies. Patients will be able to receive results from the combined workflow in as little as three weeks from a blood draw.
Financial details of the agreement were not disclosed.
"[Quantgene's] ability to unlock the human genome and further inform our decision support system for oncology complements the CureMatch precision medicine solution and supports our mission to extend and save lives."
Quantgene previously partnered with Viktor Scientific in February to launch a genomics health service.